Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, Zilli T. Ost P, et al. Among authors: bultijnck r. Eur Urol Oncol. 2024 Jun;7(3):462-468. doi: 10.1016/j.euo.2023.09.007. Epub 2023 Oct 9. Eur Urol Oncol. 2024. PMID: 37821242 Clinical Trial.
Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trial.
Berwouts D, De Wolf K, Lambert B, Bultijnck R, De Neve W, De Lobel L, Jans L, Goetghebeur E, Speleers B, Olteanu LA, Madani I, Goethals I, Ost P. Berwouts D, et al. Among authors: bultijnck r. Radiother Oncol. 2015 May;115(2):272-8. doi: 10.1016/j.radonc.2015.04.022. Epub 2015 May 14. Radiother Oncol. 2015. PMID: 25981049 Clinical Trial.
Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.
Bultijnck R, Surcel C, Ploussard G, Briganti A, De Visschere P, Fütterer J, Ghadjar P, Giannarini G, Isbarn H, Massard C, Sooriakumaran P, Valerio M, van den Bergh R, Ost P. Bultijnck R, et al. Eur Urol Focus. 2016 Dec;2(5):514-521. doi: 10.1016/j.euf.2016.02.009. Epub 2016 Mar 5. Eur Urol Focus. 2016. PMID: 28723517
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G. Ost P, et al. Among authors: bultijnck r. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial.
Rammant E, Ost P, Swimberghe M, Vanderstraeten B, Lumen N, Decaestecker K, Bultijnck R, De Meerleer G, Sarrazyn C, Colman R, Fonteyne V. Rammant E, et al. Among authors: bultijnck r. Strahlenther Onkol. 2019 May;195(5):393-401. doi: 10.1007/s00066-018-1395-y. Epub 2018 Nov 7. Strahlenther Onkol. 2019. PMID: 30406289 Clinical Trial. English.
34 results